A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer

NCT07294534 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

817

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2 + Breast Cancer

Interventions

DRUG: HLX87+HX22
DRUG: HLX87 + Pertuzumab
DRUG: TCbHP

Sponsor

Shanghai Henlius Biotech